Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Female 18 years of age or older. * Adequate hematologic, renal and hepatic function. * Competent to comprehend, sign, and date an IRB-approved informed consent form. * Subjects of childbearing potential and sexually active must provide a negative pregnancy test and use accepted and effective method of contraception. Exclusion Criteria: * Prior taxane-containing treatment within 6 months prior to enrollment. * Prior treatment including chemotherapy and/or endocrine therapy discontinued \< 21 days prior to enrollment. * More than one prior systemic chemotherapy for locally recurrent or metastatic breast cancer. * Current or prior history of central nervous system metastases. * History of arterial or venous thrombosis within 1 year prior to enrollment. * History of bleeding diathesis or bleeding within 14 days prior to enrollment. * Radiation therapy to a significant portion of bone marrow or prior history of high-dose chemotherapy requiring bone marrow or stem cell support. * Hypersensitivity to paclitaxel, docetaxel, or drugs using the vehicle cremophor. * Prior VEGFr targeted therapies within 30 days of enrollment. * Any anticoagulant therapy within 7 days prior to enrollment, except for warfarin of less than 2mg per day. * Clinically significant cardiac disease including myocardial infarction or other cardiovascular related event within 1 year before enrollment. * Uncontrolled hypertension (systolic \>150 mmHg; diastolic \> 90 mmHg). * Known HIV positive, hepatitis C positive or hepatitis B surface antigen positive. * Prior bevacizumab or trastuzumab therapy within 12 weeks of enrollment. * Non-healing wound, ulcer or fracture. * Known history of prior episodes of cholecystitis, prior biliary procedure or prior or ongoing biliary disease. * Unable to take oral medications. * Not recovered from previous therapies. * Major surgery within 28 days prior to enrollment. * Prior malignancy unless treated with curative intent and without evidence of disease for greater than 3 years before enrollment. * Peripheral neuropathy grade \> 1 per CTCAE version 3.0